|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||1.2900 - 1.3700|
|52 Week Range||0.9000 - 1.6400|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.85|
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From the US: 877-407-9208 International: 201-493-6784 Israel: 1 809 406 247 Conference ID: 13707066 Webcast: https://edge.media-server.com/mmc/p/y7tts2sv About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” phase 1 trial as well as in three VBL-sponsored tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."